← Back to Search

Glucagon-like peptide-1 receptor agonist

Liraglutide for Type 2 Diabetes

Phase 4
Waitlist Available
Led By Ajaykumar D Rao, MD
Research Sponsored by Temple University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months
Awards & highlights

Summary

This trial tests if Liraglutide can reduce stress in fat tissue and improve health in obese patients with type 2 diabetes. The medication helps control blood sugar and appetite, potentially offering better management for these patients. Liraglutide is used for weight management and glycemic control in patients with type 2 diabetes.

Who is the study for?
This trial is for obese adults aged 18-75 with type 2 diabetes, a BMI of 27-35, and HbA1c levels between 7-10%. They should be managing their diabetes with exercise, diet, metformin or similar medications. Those with certain medical conditions like medullary thyroid cancer or pancreatitis cannot join.
What is being tested?
The study aims to see if Liraglutide can reduce ER stress in fat tissue of diabetic patients. It's a single blind test where half the participants first get Liraglutide then a placebo, while the other half start with placebo followed by Liraglutide.
What are the potential side effects?
Possible side effects of Liraglutide include digestive issues like nausea and diarrhea, low blood sugar levels (hypoglycemia), allergic reactions, pancreatitis and changes in heart rate.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Body Weight Changes
Secondary outcome measures
Beta cell function
Body composition
Body weight
+3 more

Side effects data

From 2017 Phase 4 trial • 100 Patients • NCT02014740
29%
nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Liraglutide
Metformin

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: LiraglutideExperimental Treatment1 Intervention
Liraglutide will be started first with 0.6 mg/d for 1 week, then increased to 1.2 mg/d from week 2 to week 12, followed by 1.8 mg/d from week 12 to week 24.
Group II: PlaceboPlacebo Group1 Intervention
Subjects will receive placebo for 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Liraglutide
FDA approved

Find a Location

Who is running the clinical trial?

Temple UniversityLead Sponsor
302 Previous Clinical Trials
84,382 Total Patients Enrolled
Ajaykumar D Rao, MDPrincipal InvestigatorTemple University
~1 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top